Similar findings were observed in round 2, when the questions distinguished between PWMS who had started DMF as a first-line therapy and those who had switched to DMF in the last 6 months, with a slight trend toward switching PWMS reporting fewer GI AEs (see Figure, Supplemental Digital Content 5, available at http://links.lww.com/JNN/A209 ).
← all excerpts
Nursing Management of Gastrointestinal Adverse Events Associated With Delayed-Release Dimethyl Fumarate: A Global Delphi Approach.
1
—
—